Translational mapping of spatially resolved transcriptomes in human and mouse pulmonary fibrosis

Lovisa Franzén(Science for Life Laboratory), Martina Olsson Lindvall(AstraZeneca (Sweden)), Michael Hühn(AstraZeneca (Sweden)), Victoria Ptasinski(AstraZeneca (Sweden)), Laura Setyo(AstraZeneca (United Kingdom)), Benjamin P. Keith(AstraZeneca (Sweden)), Astrid Collin(AstraZeneca (Sweden)), Steven Oag(AstraZeneca (Sweden)), Thomas Volckaert(AstraZeneca (Sweden)), Annika Borde(AstraZeneca (Sweden)), Joakim Lundeberg(Science for Life Laboratory), Julia Lindgren(AstraZeneca (Sweden)), Graham Belfield(AstraZeneca (Sweden)), Sonya Jackson(AstraZeneca (Sweden)), Anna Ollerstam(AstraZeneca (Sweden)), Marianna Stamou(AstraZeneca (Sweden)), Patrik L. Ståhl(Science for Life Laboratory), Jorrit J. Hornberg(AstraZeneca (Sweden))
bioRxiv (Cold Spring Harbor Laboratory)
December 21, 2023
Cited by 3Open Access
Full Text

Abstract

Abstract Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with poor prognosis and limited treatment options. Efforts to identify effective treatments are thwarted by limited understanding of IPF pathogenesis and poor translatability of available preclinical models. To address these limitations, we generated spatially resolved transcriptome maps of human IPF and bleomycin-induced mouse lung fibrosis. We uncovered distinct fibrotic niches in the IPF lung, characterized by aberrant alveolar epithelial cells in a microenvironment dominated by TGFβ signaling alongside factors such as p53 and ApoE. We also identified a clear divergence between the arrested alveolar regeneration in the IPF fibrotic niches, and the active tissue repair in the acutely fibrotic mouse lung. Our study offers in-depth insights into the IPF transcriptional landscape and proposes alveolar regeneration as a promising therapeutic strategy for IPF.


Related Papers